Institute of Cardiometabolisme Nutrition

VÉLIZY-VILLACOUBLAY, France--(BUSINESS WIRE)-- The MEDITWIN consortium was announced on December 11, 2023, in the presence of French President Emmanuel Macron. More details were presented at the PariSanté Campus on December 14 in the presence of French Minister Delegate for Industry Roland Lescure. The consortium is made up of seven University Hospital Institutes (IHUs), Nantes University Hospital (CHU), Inria, startups and Dassault Systèmes. MEDITWIN will offer virtual twins for medical practice, helping to improve the quality of care for safer, more accessible healthcare for all. The MEDITWIN project will offer personalized virtual twins of organs, metabolism and cancer, for better diagnosis and treatment. In particular, MEDITWIN will enable doctors to simulate future scenarios for a patient. Seven new medical practices will be developed from the virtual twins, in neurology, cardiology and oncology. This will result in seven "virtual healthcare products" that will be deployed on a sovereign industrial cloud platform. The MEDITWIN project leverages the expertise of world-class partners in each of the fields covered, around the 14 founding members of this consortium: Dassault Systèmes, as the industrial leader of the consortium; seven University Hospital Institutes at the highest level of medical and scientific excellence; Nantes University Hospital via l’institut du thorax; startups inHEART, Codoc, Qairnel and Neurometers; and Inria through 11 project teams involved in this project. Virtual twins have become an indispensable asset in the aeronautics and mobility industries, where virtualization has enabled considerable progress in terms of safety, quality, ecological footprint and cost-effectiveness. MEDITWIN builds on the experience accumulated by the partners over many years in the field of virtual twins for healthcare, such as the Living Heart initiative by Dassault Systèmes (link), the Living Brain (link), as well as the activities of the PEPR digital health program co-directed by Inria and INSERM, for example. MEDITWIN will enable the industrialization, clinical validation and standardization of these innovations, so that these technologies can be deployed in a standardized way and benefit as many people as possible. The best standards of care will be incorporated into virtualized experiences made accessible worldwide, setting a new benchmark for quality in healthcare and providing a decisive learning ground for progress in medical science. The benefits of virtual twins will be assessed for medical teams, patients, and the healthcare system, notably in terms of improving the efficiency of care, quality of multidisciplinary decision-making, and effectiveness and safety of medical practices and interventions. In practice, the MEDITWIN initiative will be developed over five years, from 2024 to 2029. The partners' investment in this project will be financially supported by the French government as part of the “France 2030” plan. Partner quotes Bernard Charlès, Chairman of Dassault Systèmes “Virtual twins have successfully enabled the industrial world to transform itself more sustainably. Today, this technology is opening up new possibilities for healthcare by revealing the secrets of the human body - by understanding and representing the invisible. For 40 years, Dassault Systèmes has been a pioneer in virtual twins, and we can apply our knowledge and know-how to transform medical practice. The MEDITWIN public-private alliance is a major step forward, mobilizing the best of medicine, science and technology to serve future healthcare. The virtual twin is already a reality, and MEDITWIN will help standardize and disseminate it worldwide to benefit millions of patients.” Bruno Sportisse, CEO of Inria “Building an active digital ecosystem can only make France a European leader in digital healthcare innovation. In line with their strategic partnership signed in 2021, Inria and Dassault Systèmes are actively collaborating in the field of virtual twins in healthcare, with an aligned vision of the challenges of sovereignty and the digital transformation of healthcare. Supported by France 2030, the MEDITWIN project, resulting from ambitious collaboration between Dassault Systèmes, Inria and IHU France, demonstrates the commitment of these players to building a French industry at the forefront of emerging healthcare issues, all for the benefit of patients.” Fabrice André, CEO of IHU PRISM of Gustave Roussy “The MEDITWIN consortium is in line with PRISM's vision of developing cancer avatars to model biology at the patient level and tailor personalized therapies. PRISM will also benefit from the expertise of the other IHUs, and will be working closely with them to develop interdisciplinary projects.” Pierre JAIS, CEO of IHU LIRYC “Combining 7 IHUs, Inria and Dassault Systèmes, MEDITWIN is a remarkable public/private collaboration. This unique project opens a new era for scaled and automated preventive medicine, so critical for patients and immensely cost effective. Finally, it offers French doctors and researchers the opportunity of relying on a global industry champion in digital health for future medical research.” Pr. Didier Mutter, CEO, IHU Strasbourg “Virtual twins will be essential elements in the medicine of the future, as they will enable treatments to be simulated to provide patients with the best possible results. MEDITWIN is an exceptional project in terms of its ambition and the challenges to be met. It's also a premiere for the IHU France alliance, uniting a multidisciplinary biomedical research capability that has no parallel anywhere in the world. For IHU Strasbourg, it will be a powerful catalyst for improving the minimally invasive management of metastatic colorectal cancer, in close collaboration with two of its historical founders, Inria and the University Hospitals of Strasbourg.” Pr. Michel Paques, IHU FOReSIGHT, head of the ophthalmology 4 department and Director of the Clinical Investigation Center at the 15-20 national hospital “The integration of the FOReSIGHT IHU into the MEDITWIN consortium will enable the large-scale development of retinal microcirculation twins, enabling personalized detection and monitoring of cerebral and cardiovascular diseases in quantitative terms. This will be the first development of a quantitative microcirculatory biomarker. The FOReSIGHT IHU has developed expertise in innovative microvascular imaging using retinal imaging with adaptive optics, a technique in which France is a leader, with the help of French high-tech companies and research institutes. This approach, unique in the world, will be strengthened with Dassault Systèmes through the development of algorithms based in particular on AI to extract morphometric information from large retinal surfaces. The integration of these measurements into biomarkers that can be used directly by practitioners represents a major challenge for the transfer from the research laboratory to the consulting room.” Pr. Stanislas Lyonnet, CEO of Institut Imagine “Institut Imagine is proud to have been one of the initiators of the strategic partnership between Dassault Systèmes and Alliance IHU France on virtual twins. We are delighted to put our medical and research excellence in the field of rare diseases at the service of the MEDITWIN project. The first project, developed with Dassault Systèmes and INRIA, concerns cardiology, with a peri-surgical decision support system designed to drastically reduce the mortality rate of newborns suffering from congenital heart disease (Hypoplastic Left Heart Syndrome) thanks to a personalized virtual twin of the cardiovascular system. Our second project, developed in partnership with Dassault Systèmes and startup CODOC, concerns pediatric neurology, with a tool for managing the Multidisciplinary Board Meeting that uses a virtual twin of patients to aid medical decision-making and management of rare epilepsies, in particular Dravet syndrome. These two projects offer significant opportunities for researchers and doctors, who will be able to visualize, test, understand, and predict before experimenting on patients.” Pr. Alexis Brice, CEO of Paris Brain Institute, IHU ICM “We are delighted to collaborate closely with Dassault Systèmes and Inria within the IHU Alliance. We aim to structure an ecosystem of innovation in healthcare from which the medicine of tomorrow will emerge. The digital twin embodies the ambitions of the Institute's research: to streamline the use of health data at different scales, to model and predict the evolution of diseases, to diagnose early, and to build personalized medicine on a solid and reliable foundation. Within MEDITWIN, Paris Brain Institute will contribute its expertise in detecting Alzheimer's disease, vascular dementia and epilepsy, and in analyzing data from patient cohorts.” Pr. Stéphane Hatem, CEO of IHU ICAN and Director of the UMR 1166 Research Unit on Cardiovascular and Metabolic Diseases “Virtual twin technology opens up possibilities for novel precision and preventive medicine for cardiometabolic diseases. Its goal is to predict the personal future risk of developing a cardiovascular disease, based on individual risk pro especially the genomic signature. Such an ambition requires changing the scale of today’s research that will be achieved through the MEDITWIN project led by Dassault Systèmes and with all its partners on board.” Pr. Bertrand Cariou, Director of l’institut du thorax, CHU de Nantes “Nantes University Hospital, via ‘l’institut du thorax’, in collaboration with Dassault Systèmes engineers, will carry out developments aimed at improving the prediction of cardiovascular accidents, which represent the leading cause of mortality in industrialized countries. To achieve this goal, the researchers will use data from the SAFIR cohort, an outcome of the CHOPIN (CHOlesterol Personalized INnovation) nationwide translational research project, on patients with familial hypercholesterolemia with or without cardiovascular disease. This pilot study in a very high-risk cardiovascular population will combine clinical, multi-omics and imaging data to create a virtual twin model, which will then be validated in a larger cardiovascular population.” Todor Jeliaskov, CEO of inHEART “At inHEART, we are excited to be part of MEDITWIN and on the forefront of the digital health transformation. Within MEDITWIN, inHEART will focus on the prevention of Sudden Cardiac Death, which takes more than 800,000 lives each year. We need to move our healthcare systems from reacting to acute complications to preventing complications. Digital technologies and Artificial Intelligence are accelerating this process.” Arthur Delapalme, Co-founder and CEO of CODOC “The MEDITWIN project has succeeded in bringing together the medical expertise of several different University Hospital Institutes. In our view, this multidisciplinary approach is a fruitful way of accelerating research and rapidly bringing the benefits of innovations to patients. As CODOC, we are very proud to build one of the seven virtual twins of this project.” Stanley Durrleman, CEO of QAIRNEL “At Qairnel, we're proud to be part of the MEDITWIN project. Our virtual twins simulate the evolution of a patient in the early stages of Alzheimer's disease. The project will enable us to put these technologies into the hands of practitioners, to propose personalized management schemes and therapeutic strategies. This will enable us to respond to one of the major public health challenges of the 21st century.” Lionel Naccache, Co-Founder of Neurometers “Neurometers aims to generalize the medical use of the electroencephalogram (EEG) to quantify the cerebral signatures of consciousness and cognition. Initially developed in healthy subjects and non-communicative patients, with highly original results validated in numerous scientific publications, we have more recently discovered and reported that this approach could prove highly promising in the field of neurodegenerative diseases that impair cognition, such as Alzheimer's disease. For the first time, direct measures of cognitive functioning could be integrated into routine clinical monitoring of patients, complementing neuropsychological tests and measures of cerebral atrophy. This approach could also make it possible to evaluate the efficacy of new therapies. Our participation in the MEDITWIN project is aimed at improving the quality of our algorithms by analyzing a large cohort of patient EEG recordings in an evolutionary manner.” ### About France 2030 The France 2030 investment plan: Reflects a double ambition: sustainably transform key sectors of our economy (energy, automotive, aeronautics or space) through technological innovation, and position France not only as a player, but also as a leader in the world of tomorrow. From basic research, to the emergence of an idea to the production of a new product or service, France 2030 supports the entire life cycle of innovation until its industrialization. Is unpublished by its magnitude: €54 billion will be invested to ensure that our companies, universities and research organizations are fully successful in their transitions in these strategic sectors. The challenge: to enable them to respond competitively to the ecological and attractiveness challenges of the coming world, and to bring out the future champions of our sectors of excellence. France 2030 is defined by two cross-cutting objectives consisting in dedicating 50% of its spending to the decarbonization of the economy, and 50% to emerging players, who are the bearers of innovation without spending that is unfavorable to the environment (in the sense of the Do No Significant Harm principle). Will be implemented collectively: designed and deployed in consultation with economic, academic, local and European stakeholders to determine their strategic orientations and flagship actions. Project leaders are invited to submit their application via open, demanding and selective procedures to benefit from the support of the State. Is led by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Agency for Ecological Transition (ADEME), the French National Research Agency (ANR), Bpifrance and the Banque des Territoires. More information on: france2030.gouv.fr | @SGPI_avenir ### About Dassault Systèmes Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit Press contact: arnaud.malherbe@3ds.com About INRIA Inria is the French national research institute for digital science and technology. World-class research, technological innovation and entrepreneurial risk are its DNA. In 220 project teams, most of which are shared with major research universities, more than 3,900 researchers and engineers explore new paths, often in an interdisciplinary manner and in collaboration with industrial partners to meet ambitious challenges. As a technological institute, Inria supports the diversity of innovation pathways: from open source software publishing to the creation of technological startups (Deeptech). Press contact: laurence.goussu@inria.fr / magalie.quet@inria.fr About IHU PRISM and Gustave Roussy IHU Prism is based on a transformative vision of cancer care. It is supported by a consortium of five partners: Gustave Roussy, Université Paris-Saclay, CentraleSupelec, Inserm and Unicancer. Its aim is to better understand the biology of each patient's cancer, and to identify those with the most aggressive tumors as soon as they are diagnosed, in order to offer them a different care pathway, based on innovation, to maximize the chances of a therapeutic response. To achieve this, it relies on innovative tools and methodologies such as circulating marker analysis, artificial intelligence and organoids. Prism also aims to change the way in which cancer is viewed and classified, from an organ-based approach to a molecular one. Press contact: claire.parisel@gustaveroussy.fr About IHU Liryc Liryc is the only institute of its kind in the world dedicated to heart rhythm disorders. Liryc is committed to 4 missions: research, innovation, care and training. The aim is to gain a better understanding of the mechanisms behind these diseases, to develop therapeutic and diagnostic tools, to treat patients more effectively and to pass on the expertise acquired. Liryc brings together researchers, doctors, engineers and mathematicians from all over the world. In a unique technological environment and a dynamic ecosystem, Liryc is helping to invent the therapeutic tools of tomorrow, to meet this major public health challenge. It is one of seven university hospital institutes (IHU) created by the French government as part of the "Investissements d'Avenir" program, with the aim of boosting medical research and innovation in France. Its founders are the University of Bordeaux, the University Hospital of Bordeaux, Inria and the Nouvelle-Aquitaine region. Press contact: manon.hans@ihu-liryc.fr - 06 23 29 70 20 About IHU Strasbourg ( ) The IHU Strasbourg is a multidisciplinary institute dedicated to the creation and dissemination of innovative image-guided therapies for optimized, safe, and personalized patient care. Its goal is to establish a new standard of care for surgical patients, considering their entire treatment itinerary from preparation for surgery to their return to the norm, offering them the best possible quality of life. The Institute's missions focus on four key pillars: patient care, translational research, education and technology transfer. These missions encompass improving patients' quality of life, researching new treatments, developing innovative devices, and training and disseminating knowledge to support the ongoing evolution of the medicine of the future. Press contact: presse@ihu-strasbourg.eu About IHU FOReSIGHT Labeled IHU in 2019, the IHU FOReSIGHT aims to bring about the care of tomorrow in ophthalmology by accelerating research and access to therapeutic innovations. It was founded by the 15-20 National hospital, Sorbonne University, Inserm and the Fondation Voir et Entendre. It brings together expert centers in ophthalmology including the 15-20 National hospital and the Vision Institute of Paris, an international research center entirely dedicated to fundamental and translational research on vision diseases. Press contact: sylvie.jumel@institut-vision.org About Institut Imagine Located on the campus of the Necker-Enfants malades hospital, the Institut Imagine is a world leader in research, care and teaching on genetic diseases. Its unique architecture, designed by Jean Nouvel and Bernard Valéro, brings together 1,000 researchers, physicians, teacher-researchers, engineers and health care personnel in a single location to work with patients, with the ambition of accelerating research and diagnosis and therapeutic innovation to change the lives of families affected by genetic diseases. The Institut Imagine has been certified “Institut hospitalo universitaire” (IHU), in 2011 and 2019 and an “Institut Carnot”, in 2020. It is supported by six founding members, including AP-HP, Inserm and Université Paris Cité, as well as by private partners and patrons. Every day in France, 64 babies are born with a genetic disease. Nearly 8,000 genetic diseases affect more than 3 million people, of which nearly one in two is undiagnosed and more than 8 in 10 have no dedicated treatment. Faced with this public health emergency, the challenge is twofold: to diagnose and to cure. g Press Contact: marie.de-bazelaire@institutimagine.org About Institut du Cerveau Created in 2010, Paris Brain Institute is a leading scientific and medical research center dedicated to the study of the brain and the discovery of new treatments for diseases of the nervous system. Its innovative model brings together patients, doctors, researchers, and entrepreneurs with a common goal: to transform fundamental discoveries into therapeutic solutions via a translational and interdisciplinary approach. Located in Paris at the heart of the Pitié-Salpêtrière Hospital – the largest neurology center in Europe – Paris Brain Institute includes over 800 international experts in 27 research teams, ten cutting-edge technological platforms, a clinical investigation center, a training organization, a living lab, and a business incubator. It is based on the association of a joint research unit (Sorbonne University, Inserm, and CNRS) and a private foundation recognized as being of public utility, the ICM Foundation, in partnership with Assistance Publique–Hôpitaux de Paris. institutducerveau-icm.org Press contact: presse@icm-institute.org About IHU ICAN Created in 2011, located at the Pitié Salpêtrière Hospital, the Foundation for Innovation in CArdiometabolism and Nutrition (IHU ICAN) is a “Hospital-University Institute” and a center of excellence for translational research on cardiometabolic diseases such as diabetes, obesity, fatty liver disease (MASH), heart and vascular diseases. Our goal is to contribute to the emergence of a new personalized medicine that integrate the determinants that contribute to the risk of developing cardiometabolic diseases. With the support of its founders, the Greater Paris University Hospitals (AP-HP - Assistance Publique- Hôpitaux de Paris), the National Institute for Health and Medical Research (Inserm - Institut national de la santé et de la recherche médicale) and Sorbonne University (SU), ICAN has structured cutting-edge scientific platforms and unique expertise for translational research with a strong focus on multi-omic, new clinical imaging, data integration and artificial intelligence. IHU ICAN key figures: 170 physicians, 220 researchers, 50 active clinical trials, 6 rare disease reference centers, 4 innovative care pathways, over 6,000 scientific publications and overall more than 42,000 patients included in cohorts, registries and clinical trials. Today, ICAN is one of Europe's leading institutes for cardiovascular, metabolic and nutritional diseases, bringing together teams of basic and clinical researchers. Press contact: Francine Trocmé - f.trocme@ihuican.org About CHU de Nantes In the heart of Nantes, the University Hospital has nearly 13,000 employees who contribute to the promotion of the values of the public hospital service: equality, continuity, neutrality, and adaptability. With its nine establishments, the University Hospital of Nantes constitutes a center of excellence, healthcare recourses, and reference at both regional and interregional levels, while providing routine and local care to the 800,000 inhabitants of the Nantes/Saint-Nazaire metropolis. Located on the south bank of the Loire, a new hospital will come to fruition in 2027. It will be the foundation of the future health district, a project of European dimension. Created in 2004, l'institut du thorax is a translational research structure (CHU de Nantes/Inserm/CNRS/Nantes Université) dedicated to cardiac, vascular and metabolic diseases, combining research, clinical investigation and advanced training within a single organization. It aims at identifying genetic risk-factors, biomarkers and therapeutic targets to improve patient care, based on large, finely-documented bio-collections directly inspired by real-life patient experience and unmet medical needs. Press contact: Zakaria Gambert, zakaria.gambert@chu-nantes.fr, 07 77 25 95 47 Florane Pasquier, florane.pasquier@chu-nantes.fr, 02 53 48 28 11 About inHEART inHEART is a deep-tech healthcare startup based in Pessac, France. It’s a spin-off from INRIA, CHU de Bordeaux and Université de Bordeaux. The company develops web-based SaaS solutions for cardiologists by utilizing AI. inHEART leverages cardiac images and electrocardiograms uploaded by the physician to deliver a digital twin of the patient’s heart for cardiac arrhythmia treatment support and prevention/screening for cardiac diseases. The company has gathered substantial clinical evidence and received a Class II CE mark and 510(k) clearance. inHEART started commercializing its SaaS solution in 2022 and is rapidly growing its user base in Europe and the U.S., now available in over 140 hospitals. The company uses its vast amount of annotated clinical data to train powerful predictive AI software to prevent and screen for sudden cardiac death, stroke, and heart failure. These SaaS solutions will be released in several phases, starting in 2024.” Press Contact: Todor Jeliaskov, todor.jeliaskov@inheartmedical.com, 05 35 38 19 72 About CODOC CODOC is a healthtech company specializing in the development of business applications and the deployment of healthcare data warehouses. CODOC supports healthcare and research stakeholders in the reuse of healthcare data to accelerate research and improve patient care. Created in 2017, CODOC's solutions have proved their worth and are now deployed in some fifteen French hospitals and cited in over a hundred scientific publications. To find out more: Press contact: Mélissa Carballeda, +33 6 78 37 23 36, melissa@codoc.co About Qairnel Qairnel is a spin-off from Inria and the Paris Brain Institute. We launched docteurmemo.fr, the first digital clinic dedicated to memory impairments. Patients benefit from online screening tools and coordinated care pathways which rely on a network of partnering healthcare professionals. Generative AI tools predict the progression trajectory of each patient, and are used therefore to operate precision clinical trials faster and at lower costs with patients with well characterized progression pro Press contact: stanley.durrleman@qairnel.com About Neurometers Neurometers is a start-up company - a spin-off from the Institut du Cerveau in Paris, on the Pitié-Salpêtrière campus (APHP and Sorbonne University) - created as a result of the cognitive neuroscience work on consciousness carried out by Lionel Naccache (Sorbonne University, APHP) and Jacobo Sitt (INSERM) on healthy humans and patients suffering from disorders of consciousness. From an individual's electroencephalogram (EEG), cerebral signatures of cognition and state of consciousness are calculated and then used to train machine learning algorithms to identify a specific cognitive process or state of consciousness. Several studies have demonstrated the medical relevance of these algorithms, both in the field of consciousness disorders and in Alzheimer's disease. Press contact: lionel.naccache@icm-institute.org and jacobo.sitt@icm-institute.org View source version on businesswire.com: Contacts Dassault Systèmes Press contact: arnaud.malherbe@3ds.com Source: Dassault Systèmes View this news release online at:

Entrepreneur Harry Massey developing GEM Wearable Device TAMPA, Fl., Jan. 11, 2023 /PRNewswire/ -- Harry Massey's lifelong goal to detect, correct and protect human energy has led to the creation of Energy4Life, a GEM wearable device. Massey, who spent nearly a decade suffering from chronic fatigue syndrome after an ice climbing accident, has channeled his challenges into multiple healthcare companies focused on bioenergetics – the biology of energy in living systems – including the latest, Energy4Life. Continue Reading Energy4Life GEM Wearable "I've been thinking about this for more than 20 years. Energy4Life has raised $2 million out of its initial $5 million raise" stated Massey, who added he's preparing to launch the GEM wearable in October 2023. Energy4Life's board includes Professor Hemal Patel, Vice-Chair of Medical Research at University of California at San Diego. Studies led by Patel have shown the technology is able to increase mitochondrial density by up to 50% and protect mitochondria from reactive oxygen species damage by up to 67%, implying cellular oxidative stress reduction. Further studies are being conducted on its ability to aid energy & emotional management, reduce stress, and improve sleep and energy when needed. The board also includes investor Kitty Stonebrunner, and the President of Institute for Integrative Nutrition, Marcello Anzalone. "Our body of work is in researching the field-based control system of the body, versus the well researched chemical-based one," Massey said. "This research sits on top of giants like Albert Einstein – the field is the sole governing force of the particle – and Professor Fritz-Albert Popp who researched biophoton emission and communication in the body." Energy4Life's wearable device detects users' physical and emotional energy through their pulse, and then corrects energy in real time by providing researched photon based biosignatures through the wearable device. The protection of energy is delivered through in-app personalized meditations and biofeedback. Massey said bioenergetics is "going to revolutionize medicine by making it cost less, create less side effects and, most importantly, be more effective than chemistry-based solutions." According to a survey by the American Psychology Association: 79 percent of employees said they experienced work-related stress, and 44 percent reported physical fatigue—a 38 percent increase since 2019. In addition, when it comes to Millennials, the largest adult population, The Shaklee U.S. Health and Wellness Study found that since the pandemic began: 60 percent are concerned they may have "permanently low energy levels"; and 65 percent report that "stress is getting in the way of my happiness, success, and overall fulfillment in other areas of my life." Massey discovered his own complete lack of energy began after an ice-climbing fall when he was 21. After many chemistry based medicine attempts to regain energy failed, Massey would discover bioenergetics, propelling him to mail a letter to the leading professor in the field, Peter Fraser In the following years, Massey admitted he essentially was Fraser's "guinea pig" with his experiments. The pair started a bioenergetic company for practitioners called NES Health that now has helped more than 150,000 people regain their energy. "When I started, wearable devices and the technology to create something like Energy4Life didn't exist, but now technology has caught up, with the GEM wearable being a way to help people with a low to no barrier entry overcome chronic fatigue like I did," Massey added. Massey says he "wants the GEM wearable to showcase the life-altering effects of bioenergetics and a movement in the world, where our environment is set up for our body to heal, our minds to calm down and our spirits to shine." "Our mission of restoring humanity's energy for life extends beyond our lifetimes until the day bioenergetics becomes a conscious choice for everyone," Massey said. For more information on the GEM wearable, visit Press Contact Energy4Life [email protected] NES Health [email protected] SOURCE Energy4Life